Selected research
Industry Research
Lung Cancer Screening Software Industry Research Report 2026
Market perspective
The global Lung Cancer Screening Software market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Lung Cancer Screening Software market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Lung Cancer Screening Software market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Lung Cancer Screening Software market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Lung Cancer Screening Software include Siemens Healthineers, GE HealthCare, Philips Healthcare, Canon Medical Systems, United Imaging Healthcare, InferVision, Airdoc, VUNO and Lunit, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Lung Cancer Screening Software market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Lung Cancer Screening Software.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lung Cancer Screening Software Market by Company
Siemens Healthineers
GE HealthCare
Philips Healthcare
Canon Medical Systems
United Imaging Healthcare
InferVision
Airdoc
VUNO
Lunit
Qure.ai
Riverain Technologies
Zebra Medical Vision
Arterys
Deepwise
EverFortune AI
Lung Cancer Screening Software Segment by Type
Cloud-Based
Web-Based
Lung Cancer Screening Software Segment by Application
Hospitals
Medical Examination Institutions
Public Health Screening
Others
Lung Cancer Screening Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Screening Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Screening Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Screening Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Lung Cancer Screening Software companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cloud-Based
- Web-Based
Applications
- Hospitals
- Medical Examination Institutions
- Public Health Screening
- Others
Companies covered
- Siemens Healthineers
- GE HealthCare
- Philips Healthcare
- Canon Medical Systems
- United Imaging Healthcare
- InferVision
- Airdoc
- VUNO
- Lunit
- Qure.ai
- Riverain Technologies
- Zebra Medical Vision
- Arterys
- Deepwise
- EverFortune AI
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Lung Cancer Screening Software by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cloud-Based
- 2.2.3 Web-Based
- 2.3 Lung Cancer Screening Software by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Medical Examination Institutions
- 2.3.4 Public Health Screening
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Lung Cancer Screening Software Breakdown Data by Type
- 3.1 Global Lung Cancer Screening Software Historic Market Size by Type (2021-2026)
- 3.2 Global Lung Cancer Screening Software Forecasted Market Size by Type (2027-2032)
4 Lung Cancer Screening Software Breakdown Data by Application
- 4.1 Global Lung Cancer Screening Software Historic Market Size by Application (2021-2026)
- 4.2 Global Lung Cancer Screening Software Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Lung Cancer Screening Software Market Perspective (2021-2032)
- 5.2 Global Lung Cancer Screening Software Growth Trends by Region
- 5.2.1 Global Lung Cancer Screening Software Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Lung Cancer Screening Software Historic Market Size by Region (2021-2026)
- 5.2.3 Lung Cancer Screening Software Forecasted Market Size by Region (2027-2032)
- 5.3 Lung Cancer Screening Software Market Dynamics
- 5.3.1 Lung Cancer Screening Software Industry Trends
- 5.3.2 Lung Cancer Screening Software Market Drivers
- 5.3.3 Lung Cancer Screening Software Market Challenges
- 5.3.4 Lung Cancer Screening Software Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Lung Cancer Screening Software Players by Revenue
- 6.1.1 Global Top Lung Cancer Screening Software Players by Revenue (2021-2026)
- 6.1.2 Global Lung Cancer Screening Software Revenue Market Share by Players (2021-2026)
- 6.2 Global Lung Cancer Screening Software Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Lung Cancer Screening Software Head Office and Area Served
- 6.4 Global Lung Cancer Screening Software Players, Product Type & Application
- 6.5 Global Lung Cancer Screening Software Manufacturers Established Date
- 6.6 Global Lung Cancer Screening Software Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Lung Cancer Screening Software Market Size (2021-2032)
- 7.2 North America Lung Cancer Screening Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Lung Cancer Screening Software Market Size by Country (2021-2026)
- 7.4 North America Lung Cancer Screening Software Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Lung Cancer Screening Software Market Size (2021-2032)
- 8.2 Europe Lung Cancer Screening Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Lung Cancer Screening Software Market Size by Country (2021-2026)
- 8.4 Europe Lung Cancer Screening Software Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Lung Cancer Screening Software Market Size (2021-2032)
- 9.2 Asia-Pacific Lung Cancer Screening Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Lung Cancer Screening Software Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Lung Cancer Screening Software Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Lung Cancer Screening Software Market Size (2021-2032)
- 10.2 South America Lung Cancer Screening Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Lung Cancer Screening Software Market Size by Country (2021-2026)
- 10.4 South America Lung Cancer Screening Software Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Lung Cancer Screening Software Market Size (2021-2032)
- 11.2 Middle East & Africa Lung Cancer Screening Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Lung Cancer Screening Software Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Lung Cancer Screening Software Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Siemens Healthineers
- 12.1.1 Siemens Healthineers Company Information
- 12.1.2 Siemens Healthineers Business Overview
- 12.1.3 Siemens Healthineers Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.1.4 Siemens Healthineers Lung Cancer Screening Software Product Portfolio
- 12.1.5 Siemens Healthineers Recent Developments
- 12.2 GE HealthCare
- 12.2.1 GE HealthCare Company Information
- 12.2.2 GE HealthCare Business Overview
- 12.2.3 GE HealthCare Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.2.4 GE HealthCare Lung Cancer Screening Software Product Portfolio
- 12.2.5 GE HealthCare Recent Developments
- 12.3 Philips Healthcare
- 12.3.1 Philips Healthcare Company Information
- 12.3.2 Philips Healthcare Business Overview
- 12.3.3 Philips Healthcare Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.3.4 Philips Healthcare Lung Cancer Screening Software Product Portfolio
- 12.3.5 Philips Healthcare Recent Developments
- 12.4 Canon Medical Systems
- 12.4.1 Canon Medical Systems Company Information
- 12.4.2 Canon Medical Systems Business Overview
- 12.4.3 Canon Medical Systems Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.4.4 Canon Medical Systems Lung Cancer Screening Software Product Portfolio
- 12.4.5 Canon Medical Systems Recent Developments
- 12.5 United Imaging Healthcare
- 12.5.1 United Imaging Healthcare Company Information
- 12.5.2 United Imaging Healthcare Business Overview
- 12.5.3 United Imaging Healthcare Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.5.4 United Imaging Healthcare Lung Cancer Screening Software Product Portfolio
- 12.5.5 United Imaging Healthcare Recent Developments
- 12.6 InferVision
- 12.6.1 InferVision Company Information
- 12.6.2 InferVision Business Overview
- 12.6.3 InferVision Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.6.4 InferVision Lung Cancer Screening Software Product Portfolio
- 12.6.5 InferVision Recent Developments
- 12.7 Airdoc
- 12.7.1 Airdoc Company Information
- 12.7.2 Airdoc Business Overview
- 12.7.3 Airdoc Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.7.4 Airdoc Lung Cancer Screening Software Product Portfolio
- 12.7.5 Airdoc Recent Developments
- 12.8 VUNO
- 12.8.1 VUNO Company Information
- 12.8.2 VUNO Business Overview
- 12.8.3 VUNO Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.8.4 VUNO Lung Cancer Screening Software Product Portfolio
- 12.8.5 VUNO Recent Developments
- 12.9 Lunit
- 12.9.1 Lunit Company Information
- 12.9.2 Lunit Business Overview
- 12.9.3 Lunit Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.9.4 Lunit Lung Cancer Screening Software Product Portfolio
- 12.9.5 Lunit Recent Developments
- 12.10 Qure.ai
- 12.10.1 Qure.ai Company Information
- 12.10.2 Qure.ai Business Overview
- 12.10.3 Qure.ai Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.10.4 Qure.ai Lung Cancer Screening Software Product Portfolio
- 12.10.5 Qure.ai Recent Developments
- 12.11 Riverain Technologies
- 12.11.1 Riverain Technologies Company Information
- 12.11.2 Riverain Technologies Business Overview
- 12.11.3 Riverain Technologies Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.11.4 Riverain Technologies Lung Cancer Screening Software Product Portfolio
- 12.11.5 Riverain Technologies Recent Developments
- 12.12 Zebra Medical Vision
- 12.12.1 Zebra Medical Vision Company Information
- 12.12.2 Zebra Medical Vision Business Overview
- 12.12.3 Zebra Medical Vision Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.12.4 Zebra Medical Vision Lung Cancer Screening Software Product Portfolio
- 12.12.5 Zebra Medical Vision Recent Developments
- 12.13 Arterys
- 12.13.1 Arterys Company Information
- 12.13.2 Arterys Business Overview
- 12.13.3 Arterys Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.13.4 Arterys Lung Cancer Screening Software Product Portfolio
- 12.13.5 Arterys Recent Developments
- 12.14 Deepwise
- 12.14.1 Deepwise Company Information
- 12.14.2 Deepwise Business Overview
- 12.14.3 Deepwise Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.14.4 Deepwise Lung Cancer Screening Software Product Portfolio
- 12.14.5 Deepwise Recent Developments
- 12.15 EverFortune AI
- 12.15.1 EverFortune AI Company Information
- 12.15.2 EverFortune AI Business Overview
- 12.15.3 EverFortune AI Revenue in Lung Cancer Screening Software Business (2021-2026)
- 12.15.4 EverFortune AI Lung Cancer Screening Software Product Portfolio
- 12.15.5 EverFortune AI Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst